This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to "the bench" for basic research, as well as findings that have been applied back to "the bedside". Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer.
Translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies concerning the molecular pathways involved in tumorigenesis. Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. The vast majority of cancer cases are due to environmental risk factors. Many of these environmental factors are controllable lifestyle choices. Experimental cancer treatments are studied in clinical trials to compare the proposed treatment to the best existing treatment through translational research. The key features of the book include: 1) New screening for the development of radioprotectors: radioprotection and anti-cancer effect of β-Glucan (Enterococcus faecalis) 2) Translational perspective on hepatocellular carcinoma 3) Brachytherapy for endometrial cancer 4) Discovery of small molecule inhibitors for histone methyltransferases in cancer
This book is all about the definition and finding ways to prioritize and accelerate translation research in biomedical sciences and rapidly turning new knowledge into first-in-human studies. It represents an effort to bring together scientists active in various areas of translational research to share science and, hopefully, generate new ideas and potential collaborations. The book provides a comprehensive overview of translational work that includes significant discoveries and pioneering contributions, e.g., in immunology, gene therapy, stem cells and population sciences. It may be used as an advanced textbook by graduate students and even ambitious undergraduates in biomedical sciences. It is also suitable for non-experts, i.e. medical doctors, who wish to have an overview of some of the fundamental models in translational research. Managing the translational enterprise remains a work in progress. The world is changing rapidly, and the scientific world needs to seek new ways to ensure that discoveries get translated for patients efficiently and as quickly as possible. In addition, everyone expects the investment in biomedical research should pay dividends through effective therapeutic solutions. This unique project provides a broad collaborative approach of the international scientific team to present its view and opinion how to cross barriers to incentives for translational research in medical sciences. Contributing to the book is an international team of prominent co-authors. The book consists of unique and widely treated topics, and includes new hypotheses, data and analyses. Sample Chapter(s). Foreword (41 KB). Chapter 1: Translational Research: Lost in Complexity (305 KB). Contents: Barriers to Incentives for Translational Research; Integrating Emerging Science into Clinical Practice; Organization, Prioritization, Review and Funding for the Translational Research; Translational Sciences in Cancer Research; Translational Science in Infectious Diseases; Translation Research in Endocrinology and Nutrition; Translation Research and Neuroscience; Stem Cells and Translation Research; The Role of Translational Research in Public Health and Behavioral Sciences; Translational Epidemiology, Biostatistics and Informatics; Translational Research Outcomes and Resources. Readership: Graduate students and researchers in cancer research, pharmacology/drug discovery/pharmaceuticals, immunology, infectious diseases and public health.
Medical centers are widely recognized as vital components of the healthcare system. However, academic medical centers are differentiated from their community counterparts by their mission, which typically focuses on clinical care, education, and research. Nonetheless, community clinics/hospitals fill a critical need and play a complementary role serving as the primary sites for health care in most communities. Furthermore, it is now increasingly recognized that in addition to physicians, physician-scientists, and other healthcare-related professionals, basic research scientists also contribute significantly to the emerging inter- and cross-disciplinary, team-oriented culture of translational science. Therefore, approaches that combine the knowledge, skills, experience, expertise, and visions of clinicians in academic medical centers and their affiliated community centers and hospitals, together with basic research scientists, are critical in shaping the emerging culture of translational research so that patients from the urban as well as suburban settings can avail the benefits of the latest developments in science and medicine. ‘Integrating Clinical and Translational Research Networks—Building Team Medicine’ is an embodiment of this ethos at the City of Hope National Medical Center in Duarte, California. It includes a series of papers authored by teams of leading clinicians, basic research scientists, and translational researchers. The authors discuss how engaging and collaborating with community-based practices, where the majority of older patients with cancer receive their care, can ensure that these patients receive the highest-quality, evidence-based care. Based on our collective experience at City of Hope, we would like to stress that the success of academic-community collaborative programs not only depends on the goodwill and vision of the participants but also on the medical administration, academic leadership, and policymakers who define the principles and rules by which cooperation within the health care industry occurs. We trust that our experience embodied in this singular compendium will serve as a ‘Rosetta Stone’ for other institutions and practitioners.
This book offers a comprehensive introduction to translational efforts in breast cancer, addressing the latest approaches to precision medicine based on the current state of understanding of breast cancer. With the latest developments in breast cancer research, our understanding of the genomic changes and the oncogenic signaling cascade of breast cancer has made considerable strides. Further, the immuno-environment has been demonstrated as the barrier to clinical cancer. In addition, major advances in cancer biology, immunology, genomics and metabolism have broken new ground for designing therapeutic approaches and selecting appropriate treatments on the basis of more precise information on the individual patient. As a result of these two trends, a clearer picture of the molecular landscape of breast cancers has facilitated the development of diagnostic, prognostic and predictive biomarkers for clinical oncology. All these aspects are addressed in this volume, which offers a comprehensive resource for researchers, graduate students and oncologists in cancer research.
Being a complex disease that affects millions of people world over, cancer research has assumed great significance. Translational cancer research transforms scientific discoveries in the laboratory into clinical application to reduce incidence of cancer, morbidity and mortality. On the other hand, personalized medicine in cancer is the concept that selection of a treatment should be tailored according to the individual patient’s specific genomic characteristics, including mutations, chromosomal aberrations, protein interactions, and SNPs, and even more, taking into account the inmume system, the metabolism and maybe in the next future also the microbiome.
Cancer refers to a family of diseases, which involves an abnormal growth of cells that can invade or spread to other parts of the body. Survival rates in people suffering from cancer vary according to the cancer type and stage in which it is diagnosed. The prognosis is worse for cancers that have metastasized. Cancer survivors often develop a second primary cancer. Cancer research strives to identify possible causes and strategies for the prevention, diagnosis and treatment of cancer. It involves various aspects of molecular bioscience, cancer epidemiology and clinical trials for evaluating and comparing outcomes of different cancer therapies. Translational research in cancer seeks to understand the mechanisms of cancer development and progression, and translate such scientific findings into formulating approaches in the treatment and prevention of cancer. Clinical cancer research is devoted to the development of surgical procedures, pharmaceutical agents and medical technologies for the treatment of cancer. This book is a compilation of chapters that discuss the most vital concepts and emerging trends in the field of cancer management. The topics covered herein deal with the clinical and translational research in the field of oncology. For all readers who are interested in this field, the case studies included herein will serve as an excellent guide to develop a comprehensive understanding.
MicroRNA (miRNA) is a cutting-edge topic in the scientific and medical fields. This is a timely and specialized book focusing on the current understanding of miRNAs and the potential for their application in cancer diagnosis, prognosis, and therapeutic targets. It also provides discussion of the lessons learned from translational miRNA studies and exploration of the next steps required to advance this field. The unique book comprises 22 in-depth chapters by gathering unparalleled topics of interest in miRNAs by international team of world-renowned experts in the field. The first fifteen chapters provide comprehensive and expert perspectives on the most common cancers from bench to bedside applications, there is no current book structured in this cancer-oriented way. The next seven chapters providing thorough overviews of miRNAs and cancer stem cells; miRNAs in cancer invasion and metastasis; miRNAs in predicting radiotherapy and chemotherapy response; as well as expounding the role of miRNA in anti-cancer drug resistance and as blood-based cancer biomarkers. Furthermore, this book explicates the interplay of miRNAs in cancer metabolism and an update on the pioneering RNAi-based treatment approaches is also presented. This specialized book will contribute great to the scientific and medical community by providing the up-to-date discoveries of miRNAs and their important roles in cancer translational research.
Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.
